Talphera, Inc. (NASDAQ:TLPH – Get Free Report)’s stock price fell 0.9% on Tuesday. The stock traded as low as $1.0550 and last traded at $1.07. 62,821 shares changed hands during mid-day trading, a decline of 61% from the average session volume of 159,629 shares. The stock had previously closed at $1.08.
Analyst Ratings Changes
Several research analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Talphera in a report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Talphera in a report on Thursday, August 13th. Finally, Wall Street Zen upgraded Talphera to a “hold” rating in a research report on Saturday, August 8th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $3.00.
Check Out Our Latest Analysis on TLPH
Talphera Stock Performance
The firm has a market cap of $55.54 million, a PE ratio of -3.96 and a beta of 0.67. The stock’s fifty day moving average price is $1.20 and its 200-day moving average price is $1.05.
Talphera (NASDAQ:TLPH – Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of ($0.06). Sell-side analysts forecast that Talphera, Inc. will post -0.23 earnings per share for the current fiscal year.
About Talphera
Talphera, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for the management of acute pain. The company’s products are designed for use in medically supervised settings, including hospitals and other healthcare environments where rapid, noninvasive pain relief may be needed.
Talphera’s principal product is DSUVIA, a sublingual tablet containing sufentanil. The product was approved by the U.S. Food and Drug Administration in 2018 for the management of acute pain in adults in certified medically supervised healthcare settings.
Featured Stories
- Five stocks we like better than Talphera
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.
